2022 World Conference on Lung Cancer (ePosters)-EP08.02-129. Closing the Gaps with Blood-Based Next Generation Sequencing

Pdf Summary

In a retrospective study, researchers evaluated the use of blood-based next generation sequencing (BB NGS) in patients with advanced non-small cell lung cancer (NSCLC). The primary goal was to determine the number of patients who underwent BB NGS in addition to tissue-based (TB) NGS testing, and the secondary goal was to see if BB NGS led to a change in treatment plans. The study included 104 eligible patients treated between January 2016 and March 2020.<br /><br />The results showed that nearly a fourth of the patients had BB NGS performed at some point during their clinical course. Out of the patients who underwent both BB and TB NGS, almost 20% had discordant results, suggesting that a combined approach with both biopsies may provide the most comprehensive assessment.<br /><br />For patients with insufficient tissue or no detectable mutations on TB biopsy, BB NGS was able to detect actionable mutations and led to the initiation of treatment within an average of two weeks. This allowed for quicker treatment decisions.<br /><br />The study also found that 30.8% of patients had a change in their management based on BB NGS results. Thirteen patients (12.5%) were initiated on treatment regimens based on BB NGS, either due to faster turnaround time, insufficient tissue, or no mutations detected on TB biopsy. The median time to treatment initiation after BB NGS was drawn for these patients was 14 days.<br /><br />BB NGS offers many advantages, including quicker turnaround time, a minimally invasive nature, and the ability to address tumor heterogeneity and track development of resistance mutations. Integrating BB and TB NGS can optimize turnaround time and increase the detection of targetable mutations.<br /><br />This study adds to the growing body of research on the emerging role of liquid biopsy and BB NGS in the management of NSCLC. However, further research is needed to validate these findings and to determine the optimal use of BB NGS in clinical practice.

Asset Subtitle

Pratik Vijay Shah

Meta Tag

Speaker Pratik Vijay Shah

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

blood-based next generation sequencing

non-small cell lung cancer

tissue-based NGS testing

treatment plans

biopsies

discordant results

actionable mutations

treatment initiation

liquid biopsy